Literature DB >> 15126804

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

Grace Lu-Yao1, Therese A Stukel, Siu-Long Yao.   

Abstract

PURPOSE: We examined trends in hospitalization and death in men with prostate cancer to determine whether outcomes have changed with time in men diagnosed and treated for this disorder.
MATERIALS AND METHODS: A population based cohort study of 180973 patients with prostate cancer in the 1979 to 1996 Surveillance, Epidemiology and End Results cancer registry and 450448 admissions in the 1987 to 1996 Surveillance, Epidemiology and End Results-Medicare linked database were analyzed. ORs derived from logistic regression were used to assess time trends in mortality and hospitalization. Multinominal logistic regression was used to obtain the adjusted proportions of deaths due to various causes in different years.
RESULTS: In men with prostate cancer the risk of death from cancer was 39.7% (OR = 0.61, 95% CI = 0.56 to 0.66), which was lower in 1995 to 1996 than in 1979 to 1980. Decreases in prostate cancer death were greater than those in cardiovascular disorders (OR = 0.85, 95% CI = 0.78 to 0.92) and evident even in men with nonlocalized disease. Overall nonprostate cancer causes of mortality increased (OR = 1.65, 95% CI = 1.52 to 1.79) and ultimately exceeded that due to prostate cancer. By 1995 to 1996 the proportion of prostate cancer deaths was similar to that of cardiovascular disorders (27.7% and 26.6%, respectively) and substantially less than that of all other sources combined (45.7%). Similar effects were observed for prostate cancer (OR = 0.40, 95% CI = 0.37 to 0.42) and nonprostate cancer (OR = 2.51, 95% CI = 2.36 to 2.68) hospitalizations.
CONCLUSIONS: In men with prostate cancer decreases in prostate cancer hospitalization and mortality have been greater than those in competing diseases with time. Most deaths in patients with prostate cancer, including those with nonlocalized disease, are now due to nonprostate cancer causes.

Entities:  

Mesh:

Year:  2004        PMID: 15126804     DOI: 10.1097/01.ju.0000127740.96006.1a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Authors:  Stefano Arcangeli; Linda Agolli; Vittorio Donato
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-10

2.  Cause of death in older men after the diagnosis of prostate cancer.

Authors:  Melanie Ketchandji; Yong-Fang Kuo; Vahakn B Shahinian; James S Goodwin
Journal:  J Am Geriatr Soc       Date:  2008-11-18       Impact factor: 5.562

Review 3.  Innovations in the systemic therapy of prostate cancer.

Authors:  Dale R Shepard; Derek Raghavan
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

4.  Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.

Authors:  Alex Z Fu; Huei-Ting Tsai; Reina Haque; Marianne Ulcickas Yood; Stephen K Van Den Eeden; Andrea E Cassidy-Bushrow; Yingjun Zhou; Nancy L Keating; Matthew R Smith; David S Aaronson; Arnold L Potosky
Journal:  World J Urol       Date:  2016-04-15       Impact factor: 4.226

Review 5.  Intermittent androgen deprivation therapy in advanced prostate cancer.

Authors:  Ajjai Alva; Maha Hussain
Journal:  Curr Treat Options Oncol       Date:  2014-03

6.  [Prostate cancer, antiandrogen treatment and cardiovascular risk].

Authors:  Santiago Reinoso Hermida; Gabriel J Díaz Grávalos; Aida Robles Castiñeiras; Clara Villar Latorre; Ana López González; Antonio Ojea Calvo
Journal:  Aten Primaria       Date:  2011-01-05       Impact factor: 1.137

Review 7.  Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

Authors:  Jason E Faris; Matthew R Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

8.  Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Authors:  Michaela A Dinan; Yanhong Li; Yinghong Zhang; Suzanne B Stewart; Lesley H Curtis; Daniel J George; Shelby D Reed
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

Review 9.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 10.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.